GR3027

Research use only, not for human use.

GR3027 (Golexanolone) is a GABA-A receptor modulating steroid antagonist that selectively antagonizes the enhanced activation of GABAA receptors by neurosteroids such as allopregnanolone and THDOC.

GR3027 (Golexanolone) is a GABA-A receptor modulating steroid antagonist that selectively antagonizes the enhanced activation of GABAA receptors by neurosteroids such as allopregnanolone and THDOC; inhibits α1β2γ2L receptor 29 ± 5% of THDOC enhancement of the GABA response, does not antagonize the effect of GABA at the GABAA receptor; during the specific conditions used for the different receptors, IC50=250 nM for the α1β2γ2L GABAA receptor and 350 nM for the α5β3γ2L GABAA receptor; restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy.Sleep Disorder Phase 2 Clinical.

——

——

GR-3027 | Golexanolone

Membrane Transporter/Ion Channel

GAT

GAT

Neurological Disease

Sleep Disorder

2089238-18-4

329.484

C21H31NO2

>98% (HPLC)

——

C[C@]1([C@](CC/2)([H])[C@]3([H])CC[C@@]4([H])C[C@](O)(C#C)CC[C@]4(C)[C@@]3([H])CC1)C2=N\O

(17E)-3α-ethynyl-17-(hydroxyimino)-5α-androstan-3β-ol

(-20℃)

With Ice Pack

≥ 2 years